Clinical trials: Invasive Carcinoma
Bladder Cancer
Development of a Non-Invasive DNA Methylation-Based Assay System for the Risk Assessment of Urothelial Carcinoma
Bladder cancer ranks the ninth in worldwide cancer incidence. Approximate 90% of bladder cancer is the malignancy of urothelium tissues, the urothelial cancer (UC).
- Trial name
- NCT00867620
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Muscle-Invasive Bladder Carcinoma
a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder Cancer Patients
This study is aimed to develop a genome-based platform to predict patients who can achieve bladder preservation after neoadjuvant treatment.
- Trial name
- NCT04686149
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Yonsei University
Chronic Inflammation of Hypopharynx, Hoarseness
Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions
The aim of the project is to compare NBI endoscopy and standard endoscopic method using white light and evaluate accuracy both methods in early detection and diagnosis hypopharyngeal and laryngeal precancerous and cancerous…
- Conditions
- Chronic Inflammation of Hypopharynx, Hoarseness, Macroscopic Laryngeal Lesions, Histological Confirmation of Dysplasia
- Trial name
- NCT02217358
- Testing
- NBI endoscopy
- Where
- Czechia
- Volunteers
- 150 people
- Sponsor
- University Hospital Ostrava
Carcinoma of Urinary Bladder, Invasive
Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer
The purpose of this study is to evaluate the safety of intravesical instillation of TC-3 Hydrogel disposable device for retention of mitomycin C chemotherapeutic drug in the urinary bladder.
- Trial name
- NCT01648010
- Testing
- TC-3 gel, TC-3 gel mixed with Mitomycin C (MMC)
- Where
- 3 sites in Israel
- Volunteers
- 7 people
- Sponsor
- UroGen Pharma Ltd.
Cirrhosis, Cirrhosis, Liver
Volatile Organic Compounds for the Assessment of Liver Disease
This study aims to determine whether a breath test could be used for early detection of hepatic fibrosis, cirrhosis or hepatocellular carcinoma.
- Conditions
- Cirrhosis, Cirrhosis, Liver, Fibrosis, Liver, Hepatocellular Carcinoma
- Trial name
- VOCAL (NCT04620538)
- Testing
- Breath Analysis
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Bladder Cancer
DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr
DURANCE is a two part, phase Ib/II, multi-centre study to assess the safety and activity of S-488210/S-488211 in combination with durvalumab, in patients with non-muscle invasive bladder cancer (NMIBC).
- Trial name
- DURANCE (NCT04106115)
- Testing
- Durvalumab, S-488210/S-488211
- Where
- 7 sites in United Kingdom
- Volunteers
- 52 people
- Sponsor
- University College, London
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
This phase II trial studies the effect of calorie reduction while undergoing stereotactic ablative radiation therapy in treating patients with breast cancer.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage 2 Breast Cancer AJCC v8, Anatomic Stage 3 Breast Cancer AJCC v8
- Trial name
- NCT04959474
- Testing
- Best Practice, Stereotactic Body Radiation Therapy, Resection
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Thomas Jefferson University
Non-Muscle Invasive Bladder Cancer (NMIBC)
Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment
A Phase Ib, open label, non randomized study to measure the safety and PK characteristics of APL-1202 at steady-state in adult male and female BCG resistant NMIBC patients when it is administered alone and concurrently with BCG.
- Trial name
- NMIBC (NCT03672240)
- Testing
- APL-1202
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Asieris Pharmaceutical Technologies Co., Ltd.
Endometrial Cancer, Fallopian Tube Cancer
Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive
The purpose of this study is to determine whether narrowband imaging (NBI) makes it easier for a surgeon to see cancer. NBI is a kind of light. Normally, white light is used during surgery.
- Conditions
- Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- Trial name
- NCT01262040
- Testing
- Narrow Band Imaging (NBI)
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
NMIBC
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
This is a phase 1/2, open-label, multicenter study of intravesical Recombinant Mycobacterium Bacillus Calmette-Guérin (BCG) in participants with Non-muscle invasive bladder cancer (NMIBC) who have not received Bacillus…
- Trial name
- NCT06800963
- Testing
- Intravesical Recombinant Mycobacterium (rMBCG)
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- ImmunityBio, Inc.
Bladder Cancer
Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
Background: Many cancers produce two particular proteins. The immune system can target these to attack the cancer. The PANVAC vaccine puts genes for these proteins inside a virus vaccine so the body sees the proteins as foreign…
- Trial name
- NCT02015104
- Testing
- BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG)), PANVAC
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
To Evaluate the Characteristics of a Breast Cancer
The purpose of this pilot study is to determine the prevalence of markers of chronic and cycling hypoxia and reactive species stress (oxidative and nitrosative) in the breast cancer tumor microenvironment.
- Trial name
- NCT01055678
- Testing
- EF5, Partial or Total Mastectomy
- Where
- United States
- Sponsor
- Mark Dewhirst
Bladder Cancer Recurrent, Non-Invasive Bladder Urothelial Carcinoma
The Effect of Post-voiding Reisdual Urine on Non-muscle Invasive Bladder Cancer Recurrence and Progression
Although transurethral resection is the main treatment option for stage Ta and T1 disease, relapse is frequently detected. Tumor number, tumor size, T stage, presence of in situ carcinoma and tumor grade are risk factors for…
- Trial name
- NCT04617743
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 500 people
- Sponsor
- Istanbul Medeniyet University
Bladder Cancer
A Study for Treatment of Superficial Bladder Cancer Using OGX-427
This is a single centre, open label, phase I dose escalation trial using a modified accelerated titration design. Patients with superficial bladder tumour (Ta or T1) or CIS and candidates for transurethral resection or muscle…
- Trial name
- NCT00959868
- Testing
- OGX-427
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Vancouver Coastal Health
Non-muscle Invasive Bladder Cancer
Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients
To evaluate the clinical efficacy (median event-free survival) of APL-1202 in combination with Epirubicin hydrochloride versus Epirubicin hydrochloride alone in intermediate and high-risk chemo-refractory non-muscle invasive…
- Trial name
- ACCRUE (NCT04490993)
- Testing
- APL-1202 in combination with Epirubicin
- Where
- China
- Volunteers
- 359 people
- Sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
Muscle-Invasive Bladder Carcinoma
Effect of Urinary Indwelling Time on Early Continence After Robot-assisted Radical Cystectomy With Orthotopic Ileal Neobladder.
The clinical trial assesses the effect of urinary indwelling time on early continence after robot- assisted radical cystectomy with orthotopic ileal neobladder.
- Trial name
- NCT04966130
- Volunteers
- 96 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Non-muscle Invasive Bladder Cancer, Cystoscopy
Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer
Bladder cancer (BC) is one of the most common type of cancer globally. Due to its high incidence rate, high risk of recurrence and progression, and frequent cystoscopy surveillance, BC contributes to major healthcare costs across…
- Conditions
- Non-muscle Invasive Bladder Cancer, Cystoscopy, Recurrence, Progression
- Trial name
- NCT06235853
- Testing
- Blood serum: sUPAR, PAI-1, IL-8., Urine: IL-8, APOE, VEGF.
- Where
- Poland
- Volunteers
- 240 people
- Sponsor
- Wroclaw Medical University
Urinary Bladder Neoplasms, BCG-Induced Cystitis
Early vs Delayed Intravesical Blad-Care During BCG Therapy
Intravesical Bacillus Calmette-Guérin (BCG) therapy is the standard adjuvant treatment for patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC).
- Trial name
- PRO-GAG (NCT07495072)
- Testing
- Hyaluronic Acid and Chondroitin Sulfate (Blad-Care™)
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- BLAD-HYA Group
Non-small Cell Lung Cancer, Minimal Residual Disease
Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
The goal of this study is to develop new techniques for minimal residual disease(MRD) monitoring and to confirm the efficacy and safety of MRD-guided postoperative management for early stage non-small cell lung cancer.
- Conditions
- Non-small Cell Lung Cancer, Minimal Residual Disease, Adaptive Treatment
- Trial name
- NCT06930807
- Testing
- Adaptive postoperative management based on minimal residual disease
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Peking University People's Hospital
Non Muscle Invasive Bladder Cancer
Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
Bladder cancer is the fourth and eighth most common malignancy among men and women, respectively. About 75% of bladder cancers are diagnosed as non muscle-invasive and according to specific tumor-stage and grade characteristics…
- Trial name
- NCT03421236
- Testing
- Ty21a
- Where
- Switzerland
- Volunteers
- 25 people
- Sponsor
- Patrice Jichlinski
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.